Inventor · disambiguated record
Bruce Rehlaender
Also filed as: REHLAENDER BRUCE · REHLAENDER BRUCE N
12 granted patents·11 pending applications·161 citations·filing 2002–2025
91Inventor score
Top patents by PatentIndex Score
23 records- 0194US10925832B2Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2020·Granted Feb 23, 2021·5 cites·18 claims
- 0293US11452692B2Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2022·Granted Sep 27, 2022·2 cites·18 claims
- 0392US11890378B2Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2022·Granted Feb 6, 2024·1 cites·14 claims
- 0491US11471413B2Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2021·Granted Oct 18, 2022·2 cites·21 claims
- 0590US7030082B2Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewithNOBEX CORP·Filed 2003·Granted Apr 18, 2006·38 cites·72 claims
- 0690US6867183B2Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewithNOBEX CORP·Filed 2002·Granted Mar 15, 2005·47 cites·133 claims
- 0789US10933020B2Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2019·Granted Mar 2, 2021·5 cites·46 claims
- 0889US6770625B2Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewithNOBEX CORP·Filed 2002·Granted Aug 3, 2004·49 cites·130 claims
- 0988US11311522B1Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamideCAVION INC·Filed 2021·Granted Apr 26, 2022·3 cites·25 claims
- 1078US7196059B2Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewithBIOCON LTD·Filed 2003·Granted Mar 27, 2007·9 cites·34 claims
- 1173US2021154146A1Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1272US2019350959A1Injectable formulations for treating cancerEPIZYME INC·Filed 2019·Application pending·0 cites
- 1371US2021353661A1Injectable formulations for treating cancerEPIZYME INC·Filed 2021·Application pending·0 cites
- 1467US12383539B2Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamideCAVION INC·Filed 2019·Granted Aug 12, 2025·0 cites·32 claims
- 1567US2020397811A1Injectable formulations for treating cancerEPIZYME INC·Filed 2020·Application pending·0 cites
- 1666US2025312323A1Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamideCAVION INC·Filed 2025·Application pending·0 cites
- 1764US2019388335A1Injectable formulations for treating cancerEPIZYME INC·Filed 2019·Application pending·0 cites
- 1862US2021251887A1Injectable formulations for treating cancerEPIZYME INC·Filed 2020·Application pending·0 cites
- 1960US2021267739A1Devices and methods for continuous drug delivery via the mouthSYNAGILE CORP·Filed 2020·Application pending·0 cites
- 2053US2017290765A1Injectable formulations for treating cancerEPIZYME INC·Filed 2015·Application pending·0 cites
- 2152US2016278899A1Devices and methods for continuous drug delivery via the mouthSYNAGILE CORP·Filed 2014·Application pending·0 cites
- 2248US11179377B2Pharmaceutical compositions and uses thereofEMBERA NEUROTHERAPEUTICS INC·Filed 2018·Granted Nov 23, 2021·0 cites·8 claims
- 2339US2018344749A1Controlled release formulations of saliclate-releasing activesCOGWELLIN LLC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Bruce Rehlaender files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →